Journal of Exotic Pet Medicine
Volume 15, Issue 1 , Pages 66-69 , January 2006

Enrofloxacin

  • Mark A. Mitchell, DVM, MS, PhD

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Dr. Mark A. Mitchell, School of Veterinary Medicine, Department of Veterinary Clinical Sciences, Louisiana State University, Skip Bertram Drive, Baton Rouge, LA 70803.

References 

  1. Hooper D , Wolfson J . The fluoroquinolones (structures, mechanisms of action and resistance and spectra of activity in vitro) . Antimicrob Agents Chemotherap . 1985;28:581–586
  2. Vancutsem PM , Babish JG , Schwark WS . The fluoroquinolone antimicrobials (structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity) . Cornell Vet . 1990;80:173–186
  3. Scheer M . Studies on the antibacterial activity of Baytril® . Vet Med Review . 1987;2:90–98
  4. Parpia S , Nix D , Hejmanowski H , et al.   Sucralfate reduces the gastrointestinal absorption of norfloxacin . Antimicrob Agents Chemotherap . 1989;33:99–102
  5. Montay G , Goueffon Y , Roquet F . Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans . Antimicrob Agents Chemotherp . 1984;25:463–472
  6. Oomori Y , Yasue T , Aoyama H , et al.   Effects of fleroxacin on HeLa cell functions and topoisomerase II . J Antimicrob Chemotherap . 1988;22(suppl D):91–97
  7. Hussy P , Maass G , Tummler B , et al.   Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts . Antimicrob Agents Chemotherap . 1986;29:1073–1078
  8. Diver JM , Wise R . Morphological and biochemical changes in Escherichia coli after exposure to ciprofloxacin . J Antimicrob Chemotherap . 1986;18(suppl D):31–41
  9. Easom CSF , Crane JP . Uptake of ciprofloxacin by human neutrophils . J Antimicrob Chemotherap . 1983;23:284–288
  10. Piddock L , Wise R . Mechanisms of resistance to quinolones and clinical perspectives . J Antimicrob Therap . 1989;23:475–481
  11. Neu HC . Bacterial resistance to fluoroquinolones . Rev Infect Dis . 1988;10(suppl D):57–63
  12. Bellido F , Pechere JC . Laboratory survey of fluoroquinolone activity . Rev Infect Dis . 1989;11(suppl 5):917–924
  13. Kato M , Onodera T . Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats . Fund Applied Toxicol . 1988;11:110–119
  14. Burkhardt J , Hill MA , Carlton WW , et al.   Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone . Vet Pathol . 1990;27:162–170
  15. Bendele AM , Hulman JF , Harvey AK , et al.   Passive role of articular chondrocytes in quinolone induced arthropathy in guinea pigs . Toxicol Pathol . 1990;18:304–312
  16. Berg J . In: Clinical indications for enrofloxacin in domestic animals and poultry, in Quinolones: A Symposium: A new class of antimicrobial agents for use in veterinary medicine . Shawnee, KS: Mobay Corporation; 1988;p. 25–34
  17. Schluter G . Ciprofloxacin (review of potential toxicologic effects) . Am J Med . 1987;82(suppl 4A):91–93
  18. Ball P . Ciprofloxacin (An overview of adverse experiments) . J Antimicrob Chemotherap . 1986;18(suppl D): 197-193
  19. Spiecker R . Untersuchungen zur Wirksamkeit des Chinoloncarbonsaure derivats. Bay Vp 2674 bei der Behandlung der latenten Salmonellen Infektion des Rindes. Dissertation . Hannover, West-Germany: Tierartzliche Hochschule; 1986;
  20. Bauditz R . Results of clinical studies with Baytril in calves and pigs . Vet Med Review . 1987;2:122–129
  21. Hungerford C , Spelman L , Papich MG . In: Pharmacokinetics of enrofloxacin after oral and intramuscular administration in Savannah monitors (Varanus exanthematicus) . Houston, TX: AAZV; 1997;p. 89–92 Proceedings of the American Association of Zoo Veterinarians, October 28-30, 1997
  22. Young LA , Schumacher J , Jacobson E , et al.   Disposition of enrofloxacin and its metabolite ciprofloxacin after IM injection in Burmese pythons (Python molurus bivittatus) . J Zoo Wildl Med . 1997;28:71–79
  23. Helmick KE , Papich MG , Vliet KA , et al.   Pharmacokinetics of enrofloxacin after single-doe oral and intravenous administration in the American alligator (Alligator mississipiensis) . J Zoo Wildl Med . 2004;35:333–340
  24. Raphael BL , Papich M , Cook RA . Pharmacokinetics of enrofloxacin after a single intramuscular injection in Indian star tortoises (Geochelone elegans) . J Zoo Wildl Med . 1994;25:88–94
  25. Flammer K , Aucoin DP , Whitt DA , et al.   Plasma concentrations of enrofloxacin in African grey parrots treated with medicated water . Avian Dis . 1990;34:1017–1022
  26. Harrenstein LA , Tell LA , Vulliet R , et al.   Disposition of enrofloxacin in red-tailed hawks (Buteo jamaicensis) and great-horned owls (Bubo virginianus) after a single oral, intramuscular, or intravenous dose . J Avian Med Surg . 2000;14:228–236
  27. Broome RL , Brooks DL , Babish JG , et al.   Pharmacokinetic properties of enrofloxacin in rabbits . Am J Vet Res . 1991;52:1835–1841
  28. Aramayona JJ , Mora J , Fraile LJ , et al.   Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drugs in lactating rabbits and neonatal offspring . Am J Vet Res . 1996;57:547–553
  29. Carpenter JW . Exotic Animal Formulary . (ed 3).. St. Louis, MO: Elsevier Saunders; 2005;

PII: S1557-5063(05)00107-2

doi: 10.1053/j.jepm.2005.11.011

Journal of Exotic Pet Medicine
Volume 15, Issue 1 , Pages 66-69 , January 2006

Article Tools